International Journal of Reproductive BioMedicine

Published date: Apr 26 2025

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 23, Issue No. 2

Pages: 111 – 130

DOI: 10.18502/ijrm.v23i2.18476

Jiut Ram Kesharijiutram@rediffmail.comDepartment of Biochemistry, Indira Gandhi Institute of Medical Sciences, Patna, Bihar

Pritam PrakashDepartment of Biochemistry, Indira Gandhi Institute of Medical Sciences, Patna, Bihar

Seema Rani SinhaDepartment of Biochemistry, Indira Gandhi Institute of Medical Sciences, Patna, Bihar

Prem PrakashDepartment of General Surgery, Indira Gandhi Institute of Medical Sciences, Patna, Bihar

Kirti RaniDepartment of Biochemistry, Indira Gandhi Institute of Medical Sciences, Patna, Bihar

Tarique AzizDepartment of Biochemistry, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand

Shaily ShilpaDepartment of Biochemistry, Indira Gandhi Institute of Medical Sciences, Patna, Bihar

Background: Recent studies reveal an association between increased cell-free fetal (cff) nucleic acid in maternal blood and pregnancy challenges like loss, pre-eclampsia, growth restriction, and preterm labor. Objective: This article assesses the role of cff nucleic acids as potential diagnostic markers for the prediction and monitoring progression of severe pregnancy-related complications.

Materials and Methods: In this systematic review and meta-analysis, various databases were searched. Original articles reporting on the role of cff nucleic acids in predicting the complications of pregnancy were included. I square test and funnel plot were used to analyze heterogeneity and publication bias, respectively. The quality of studies was assessed using the critical appraisal checklists for studies created by the Joanna Briggs Institute.

Results: 70 publications were selected for the final qualitative analysis. Articles were published between 2010 and 2023, and most studies were conducted in the USA and China. The majority of studies were conducted on the quantity of cff-DNA (n = 40), and the remaining on microRNA (n = 18), messenger RNA (n = 11), and cell-free RNA (n = 1). The pooled sensitivity of cff nucleic acids for detecting trisomy was found to be 90.9 (95% CI: 80.9–100%). MicroRNA levels were significantly increased in participants with gestational diabetes mellitus, with a standardized mean difference of 1.22 (95% CI: -0.90–3.34).

Conclusion: Fetal nucleic acids can serve as accurate noninvasive diagnostic tools for predicting serious complications during pregnancy.

Keywords: Cell-free nucleic acid, Pregnancy, Messenger RNA, MicroRNA, Gestational diabetes

[1] Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update 2009; 15: 139–151.

[2] Mujezinovic F, Prosnik A, Alfirevic Z. Different communication strategies for disclosing results of diagnostic prenatal testing. Cochrane Database Syst Rev 2010; 11: CD007750.

[3] Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485–487.

[4] Rose NC, Barrie ES, Malinowski J, Jenkins GP, McClain MR, LaGrave D, et al. Systematic evidence-based review: The application of noninvasive prenatal screening using cell-free DNA in general-risk pregnancies. Genet Med 2022; 24: 1379–1391.

[5] Carbone IF, Conforti A, Picarelli S, Morano D, Alviggi C, Farina A. Circulating nucleic acids in maternal plasma and serum in pregnancy complications: Are they really useful in clinical practice? A systematic review. Mol Diagn Ther 2020; 24: 409–431.

[6] Garshasbi M, Wang Y, Hantoosh Zadeh S, Giti S, Piri S, Hekmat MR. Clinical application of cell-free DNA sequencing-based noninvasive prenatal testing for trisomies 21, 18, 13 and sex chromosome aneuploidy in a mixed-risk population in Iran. Fetal Diagn Ther 2020; 47: 220–227.

[7] Luo Y, Xu L, Ma Y, Yan X, Hou R, Huang Y, et al. Association between the first and second trimester cell-free DNA fetal fraction and spontaneous preterm birth. Expert Rev Mol Diagn 2023; 23: 635–642.

[8] Moufarrej MN, Vorperian SK, Wong RJ, Campos AA, Quaintance CC, Sit RV, et al. Early prediction of preeclampsia in pregnancy with cell-free RNA. Nature 2022; 602: 689–694.

[9] Qin S, Sun N, Xu L, Xu Y, Tang Q, Tan L, et al. The value of circulating microRNAs for diagnosis and prediction of preeclampsia: A meta-analysis and systematic review. Reprod Sci 2022; 29: 3078–3090.

[10] Yin Y, Liu M, Yu H, Zhang J, Zhou R. Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020; 253: 121–132.

[11] Rafaeli-Yehudai T, Imterat M, Douvdevani A, Tirosh D, Benshalom-Tirosh N, Mastrolia SA, et al. Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation. PLoS One 2018; 13: e0200360.

[12] Sifakis S, Koukou Z, Spandidos DA. Cell-free fetal DNA and pregnancy-related complications (review). Mol Med Rep 2015; 11: 2367–2372.

[13] Nadeau-Vallée M, Obari D, Palacios J, Brien MÈ, Duval C, Chemtob S, et al. Sterile inflammation and pregnancy complications: A review. Reproduction 2016; 152: R277-R292.

[14] Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 2011; 39: 91–92.

[15] JBI critical appraisal tools. Available at: https://jbi.global/critical-appraisal-tools.

[16] Schlaikjær Hartwig T, Ambye L, Gruhn JR, Petersen JF, Wrønding T, Amato L, et al. Cell-free fetal DNA for genetic evaluation in Copenhagen pregnancy loss study (COPL): A prospective cohort study. Lancet 2023; 401: 762–771.

[17] Dugoff L, Koelper NC, Chasen ST, Russo ML, Roman AS, Limaye MA, et al. Cell-free DNA screening for trisomy 21 in twin pregnancy: A large multicenter cohort study. Am J Obstet Gynecol 2023; 229: 435.

[18] Dar P, Jacobsson B, MacPherson C, Egbert M, Malone F, Wapner RJ, et al. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. Am J Obstet Gynecol 2022; 227: 259.

[19] Afzal M, Naeem MA, Ahmed S, Amin N, Rahim A, Munawar M, et al. Noninvasive prenatal testing of beta-thalassemia for common Pakistani mutations: A comparative study using cell-free fetal DNA from maternal plasma and chorionic villus sampling. Hematology 2022; 27: 353–359.

[20] Chen M, Su F, Wang J, Zhou L, Liu Q, Chai X, et al. Temporal persistence of residual fetal cell-free DNA from a deceased cotwin after selective fetal reduction in dichorionic diamniotic twin pregnancies. Prenat Diagn 2021; 41: 1602–1610.

[21] Bevilacqua E, Jani JC, Chaoui R, Suk EKA, Palma-Dias R, Ko TM, et al. Performance of a targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort. Ultrasound Obstet Gynecol 2021; 58: 597–602.

[22] Amaral LM, Sandrim VC, Kutcher ME, Spradley FT, Cavalli RC, Tanus-Santos JE, et al. Circulating total cell-free dna levels are increased in hypertensive disorders of pregnancy and associated with prohypertensive factors and adverse clinical outcomes. Int J Mol Sci 2021; 22: 564.

[23] Yuan X, Zhou L, Zhang B, Wang H, Yu B, Xu J. Association between low fetal fraction of cell-free DNA at the early second-trimester and adverse pregnancy outcomes. Pregnancy Hypertens 2020; 22: 101–108.

[24] Shook LL, Clapp MA, Roberts PS, Bernstein SN, Goldfarb IT. High fetal fraction on first trimester cell-free dna aneuploidy screening and adverse pregnancy outcomes. Am J Perinatol 2020; 37: 8–13.

[25] Migliorini S, Saccone G, Silvestro F, Massaro G, Arduino B, D’Alessandro P, et al. First-trimester screening based on cell-free DNA vs combined screening: A randomized clinical trial on women’s experience. Prenat Diagn 2020; 40: 1482–1488.

[26] Yuan X, Zhou L, Zhang B, Wang H, Jiang J, Yu B. Early second-trimester plasma cell-free DNA levels with subsequent risk of pregnancy complications. Clin Biochem 2019; 71: 46–51.

[27] Yoffe L, Polsky A, Gilam A, Raff C, Mecacci F, Ognibene A, et al. Early diagnosis of gestational diabetes mellitus using circulating microRNAs. Eur J Endocrinol 2019; 181: 565–577.

[28] Menon R, Debnath C, Lai A, Guanzon D, Bhatnagar S, Kshetrapal PK, et al. Circulating exosomal mirna profile during term and preterm birth pregnancies: A longitudinal study. Endocrinology 2019; 160: 249–275.

[29] Long Y, Chen Y, Fu XQ, Yang F, Chen ZW, Mo GL, et al. Research on the expression of MRNA-518b in the pathogenesis of placenta accreta. Eur Rev Med Pharmacol Sci 2019; 23: 23–28.

[30] Li J, Zhang N, Zhang Y, Hu X, Gao G, Ye Y, et al. Human placental lactogen mRNA in maternal plasma play a role in prenatal diagnosis of abnormally invasive placenta: Yes or no? Gynecol Endocrinol 2019; 35: 631–634.

[31] Hromadnikova I, Dvorakova L, Kotlabova K, Krofta L. The prediction of gestational hypertension, preeclampsia and fetal growth restriction via the first trimester screening of plasma exosomal C19MC microRNAs. Int J Mol Sci 2019; 20: 2972.

[32] Guo FF, Yang JX, Huang YL, Qi YM, Hou YP, Peng HS, et al. Association between fetal fraction at the second trimester and subsequent spontaneous preterm birth. Prenat Diagn 2019; 39: 1191–1197.

[33] Gerson KD, Truong S, Haviland MJ, O’Brien BM, Hacker MR, Spiel MH. Low fetal fraction of cell-free DNA predicts placental dysfunction and hypertensive disease in pregnancy. Pregnancy Hypertens 2019; 16: 148–153.

[34] Darghahi R, Mobaraki-Asl N, Ghavami Z, Pourfarzi F, Hosseini-Asl S, Jalilvand F. Effect of cell-free fetal DNA on spontaneous preterm labor. J Adv Pharm Technol Res 2019; 10: 117–120.

[35] Cook J, Bennett PR, Kim SH, Teoh TG, Sykes L, Kindinger LM, et al. First trimester circulating microrna biomarkers predictive of subsequent preterm delivery and cervical shortening. Sci Rep 2019; 9: 5861.

[36] Bender WR, Koelper NC, Sammel MD, Dugoff L. Association of fetal fraction of cell-free DNA and hypertensive disorders of pregnancy. Am J Perinatol 2019; 36: 311–316.

[37] Wommack JC, Trzeciakowski JP, Miranda RC, Stowe RP, Ruiz RJ. Micro RNA clusters in maternal plasma are associated with preterm birth and infant outcomes. PLoS One 2018; 13: e0199029.

[38] Suzumori N, Sekizawa A, Ebara T, Samura O, Sasaki A, Akaishi R, et al. Fetal cell-free DNA fraction in maternal plasma for the prediction of hypertensive disorders of pregnancy. Eur J Obstet Gynecol Reprod Biol 2018; 224: 165–169.

[39] Rolnik DL, da Silva Costa F, Lee TJ, Schmid M, McLennan AC. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia. Ultrasound Obstet Gynecol 2018; 52: 722–727.

[40] Pheiffer C, Dias S, Rheeder P, Adam S. Decreased expression of circulating miR-20a-5p in South African women with gestational diabetes mellitus. Mol Diagn Ther 2018; 22: 345–352.

[41] Ngo TTM, Moufarrej MN, Rasmussen MLH, Camunas-Soler J, Pan W, Okamoto J, et al. Noninvasive blood tests for fetal development predict gestational age and preterm delivery. Science 2018; 360: 1133–1136.

[42] Morano D, Rossi S, Lapucci C, Pittalis MC, Farina A. Cell-free DNA (cfDNA) fetal fraction in early- and late-onset fetal growth restriction. Mol Diagn Ther 2018; 22: 613–619.

[43] Lamadrid-Romero M, Solís KH, Cruz-Reséndiz MS, Pérez JE, Díaz NF, Flores-Herrera H, et al. Central nervous system development-related microRNAs levels increase in the serum of gestational diabetic women during the first trimester of pregnancy. Neurosci Res 2018; 130: 8–22.

[44] Wander PL, Boyko EJ, Hevner K, Parikh VJ, Tadesse MG, Sorensen TK, et al. Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes. Diabetes Res Clin Pract 2017; 132: 1–9.

[45] Silver RM, Myatt L, Hauth JC, Leveno KJ, Peaceman AM, Ramin SM, et al. Cell-free total and fetal dna in first trimester maternal serum and subsequent development of preeclampsia. Am J Perinatol 2017; 34: 191–198.

[46] Muñoz-Hernández R, Medrano-Campillo P, Miranda ML, Macher HC, Praena-Fernández JM, Vallejo-Vaz AJ, et al. Total and fetal circulating cell-free DNA, angiogenic, and antiangiogenic factors in preeclampsia and HELLP syndrome. Am J Hypertens 2017; 30: 673–682.

[47] Ershova E, Sergeeva V, Klimenko M, Avetisova K, Klimenko P, Kostyuk E, et al. Circulating cell-free DNA concentration and DNase I activity of peripheral blood plasma change in case of pregnancy with intrauterine growth restriction compared to normal pregnancy. Biomed Rep 2017; 7: 319–324.

[48] Whitehead CL, McNamara H, Walker SP, Alexiadis M, Fuller PJ, Vickers DK, et al. Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks’ gestation. Am J Obstet Gynecol 2016; 214: 521.

[49] Thurik FF, Lamain-de Ruiter M, Javadi A, Kwee A, Woortmeijer H, Page-Christiaens GC, et al. Absolute first trimester cell-free DNA levels and their associations with adverse pregnancy outcomes. Prenat Diagn 2016; 36: 1104–1111.

[50] Krishna I, Badell M, Loucks TL, Lindsay M, Samuel A. Adverse perinatal outcomes are more frequent in pregnancies with a low fetal fraction result on noninvasive prenatal testing. Prenat Diagn 2016; 36: 210–215.

[51] Dugoff L, Barberio A, Whittaker PG, Schwartz N, Sehdev H, Bastek JA. Cell-free DNA fetal fraction and preterm birth. Am J Obstet Gynecol 2016; 215: 231.

[52] AbdelHalim RM, Ramadan DI, Zeyada R, Nasr AS, Mandour IA. Circulating maternal total cell-free DNA, cell-free fetal DNA and soluble endoglin levels in preeclampsia: Predictors of adverse fetal outcome? A cohort study. Mol Diagn Ther 2016; 20: 135–149.

[53] Quezada MS, Francisco C, Dumitrascu-Biris D, Nicolaides KH, Poon LC. Fetal fraction of cell-free DNA in maternal plasma in the prediction of spontaneous preterm delivery. Ultrasound Obstet Gynecol 2015; 45: 101–105.

[54] Naghshineh E, Khorvash E, Kamali S. A comparison of cell-free placental messenger ribonucleic acid and color Doppler ultrasound for the prediction of placental invasion in patients with placenta accreta. Adv Biomed Res 2015; 4: 31.

[55] Elovitz MA, Anton L, Bastek J, Brown AG. Can microRNA profiling in maternal blood identify women at risk for preterm birth? Am J Obstet Gynecol 2015; 212: 782.

[56] Clark-Ganheart CA, Fries MH, Leifheit KM, Jensen TJ, Moreno-Ruiz NL, Ye PP, et al. Use of cell-free DNA in the investigation of intrauterine fetal demise and miscarriage. Obstet Gynecol 2015; 125: 1321–1329.

[57] Zhou J, Li J, Yan P, Ye YH, Peng W, Wang S, et al. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Placenta 2014; 35: 691–695.

[58] Zanello M, Sekizawa A, Purwosunu Y, Curti A, Farina A. Circulating mRNA for the PLAC1 gene as a second trimester marker (14–18 weeks’ gestation) in the screening for late preeclampsia. Fetal Diagn Ther 2014; 36: 196–201.

[59] Luque A, Farwati A, Crovetto F, Crispi F, Figueras F, Gratacós E, et al. Usefulness of circulating microRNAs for the prediction of early preeclampsia at first-trimester of pregnancy. Sci Rep 2014; 4: 4882.

[60] Korabecna M, Ulcova-Gallova Z, Horinek A, Pazourková E, Calda P. Quantification of circulating fetal DNA as a tool for potential monitoring of pregnant patients with antiphospholipid antibodies. Autoimmunity 2014; 47: 473–477.

[61] Zanello M, DeSanctis P, Pula G, Zucchini C, Pittalis MC, Rizzo N, et al. Circulating mRNA for epidermal growth factor-like domain 7 (EGFL7) in maternal blood and early intrauterine growth restriction: A preliminary analysis. Prenat Diagn 2013; 33: 168–172.

[62] Zamanpoor M, Rosli R, Yazid MN, Husain Z, Nordin N, Thilakavathy K. Quantitative analysis of fetal DNA in maternal plasma in gestational diabetes mellitus, iron deficiency anemia and gestational hypertension pregnancies. J Matern Fetal Neonatal Med 2013; 26: 960–966.

[63] Whitehead CL, Walker SP, Ye L, Mendis S, Kaitu’u-Lino TJ, Lappas M, et al. Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab 2013; 98: E429-E436.

[64] Samuel A, Bonanno C, Oliphant A, Batey A, Wright JD. Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study. Prenat Diagn 2013; 33: 1050–1053.

[65] Poon LCY, Musci T, Song K, Syngelaki A, Nicolaides KH. Maternal plasma cell-free fetal and maternal DNA at 11–13 weeks’ gestation: Relation to fetal and maternal characteristics and pregnancy outcomes. Fetal Diagn Ther 2013; 33: 215–223.

[66] Lim JH, Kim MH, Han YJ, Lee DE, Park SY, Han JY, et al. Cell-free fetal DNA and cell-free total DNA levels in spontaneous abortion with fetal chromosomal aneuploidy. PLoS One 2013; 8: e56787.

[67] Wu L, Zhou H, Lin H, Qi J, Zhu C, Gao Z, et al. Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies. Reproduction 2012; 143: 389–397.

[68] Jakobsen TR, Clausen FB, Rode L, Dziegiel MH, Tabor A. High levels of fetal DNA are associated with increased risk of spontaneous preterm delivery. Prenat Diagn 2012; 32: 840–845.

[69] Ayala Ramírez P, García Robles R, Rojas JD, Bermúdez M, Bernal J. Identification of messenger RNA of fetoplacental source in maternal plasma of women with normal pregnancies and pregnancies with intrauterine growth restriction. Colomb Med 2012; 43: 184–188.

[70] Zhao C, Dong J, Jiang T, Shi Z, Yu B, Zhu Y, et al. Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One 2011; 6: e23925.

[71] Yang Q, Lu J, Wang S, Li H, Ge Q, Lu Z. Application of next-generation sequencing technology to profile the circulating microRNAs in the serum of preeclampsia versus normal pregnant women. Clin Chim Acta 2011; 412: 2167–2173.

[72] Paiva P, Whitehead C, Saglam B, Palmer K, Tong S. Measurement of mRNA transcripts of very high placental expression in maternal blood as biomarkers of preeclampsia. J Clin Endocrinol Metab 2011; 96: E1807–1815.

[73] Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci 2011; 18: 46–56.

[74] Illanes S, Gomez R, Fornes R, Figueroa-Diesel H, Schepeler M, Searovic P, et al. Free fetal DNA levels in patients at risk of preterm labour. Prenat Diagn 2011; 31: 1082–1085.

[75] Gunel T, Zeybek YG, Akçakaya P, Kalelioğlu I, Benian A, Ermis H, et al. Serum microRNA expression in pregnancies with preeclampsia. Genet Mol Res 2011; 10: 4034–4040.

[76] Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 2011; 204: 178.

[77] Mouillet JF, Chu T, Hubel CA, Nelson DM, Parks WT, Sadovsky Y. The levels of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Placenta 2010; 31: 781–784.

[78] Hromadnikova I, Zejskova L, Kotlabova K, Jancuskova T, Doucha J, Dlouha K, et al. Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences-evaluation of diagnostic possibilities for predicting placental insufficiency. DNA Cell Biol 2010; 29: 295–301.

[79] Galbiati S, Causarano V, Pinzani P, Francesca S, Orlando C, Smid M, et al. Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy. Clin Chem Lab Med 2010; 48: 791–794.

[80] Farina A, Zucchini C, Sekizawa A, Purwosunu Y, de Sanctis P, Santarsiero G, et al. Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10–14 weeks. Am J Obstet Gynecol 2010; 203: 575.

[81] El Behery MM, Rasha LE, El Alfy Y. Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta. Int J Gynaecol Obstet 2010; 109: 30–33.

[82] Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: Updated meta-analysis. Ultrasound Obstet Gynecol 2017; 50: 302–314.

[83] Dinesen S, El-Faitarouni A, Frisk NLS, Sørensen AE, Dalgaard LT. Circulating microRNA as biomarkers for gestational diabetes mellitus: A systematic review and meta-analysis. Int J Mol Sci 2023; 24: 6186.